CYP19A1 and polycystic ovary syndrome: In contrast, high doses of DCI, either in combination with MI [16] or alone at supraphysiological levels [17], resulted in abnormal ovarian histology, decreased aromatase expression, altered steroidogenic activity in ovarian cells, and an androgenic phenotype that closely mirrors the clinical features of PCOS patients.